ArticleAnnals of hematology2025

Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.

Gaetano Cimino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.